Abstract 130P
Background
At the population level, it is useful to estimate the liver cancer risk based on lifestyle factors and regular biomarkers to encourage high-risk people to be screened. Therefore, we conducted the current study to develop a prediction model for the stratification of liver cancer risk among the general population in China.
Methods
112 440 subjects aged 20-80 years from Kailuan Cohort were included in the current study. A total of 326 incident primary liver cancer occurred during 913 078.51 person-years of follow-up. We used the Cox proportional hazards regression model to obtain coefficients for each predictor in the 8-year prediction models among a random two thirds of participants. The prediction models were validated in the remaining one third of participants. Hosmer-Lemeshow’s statistic and Harrell’s C-index were used to evaluate calibration and discrimination, respectively.
Results
A full prediction model that comprised of nine predictors, including age, sex, smoking pack-years, alcohol drinking, tea consumption, diabetes and fasting blood glucose (FBG) level, total cholesterol (TC), alanine aminotransferase (ALT), and hepatitis B virus surface antigen (HBsAg), was derived. The model showed good calibration (χ2=3.57, P = 0.89) and discrimination (Harrell’s C-index=0.85; 95% confidence interval [CI]: 0.81, 0.88) in the validation data set.
Conclusions
A practical liver prediction model based on accessible indicators combined with lifestyle factors, regular blood biomarkers, and hepatitis virus status was developed, which allows to stratify the risk of liver cancer among the general population. Because the factors in this model are able to be acquired from questionnaire and blood detection, it has great potential to be translated into practical use for public health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R& D Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract